comprehensive -WSS

comprehensive

author：explore 2025-09-27 12:54:03 - browse：537

Steven Pearson — ICER President Steven D. Pearson Craig F. Walker/The Boston Globe

Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. But a meeting Thursday at the Massachusetts Institute of Technology may prove to be the exception to that rule.

Patients Rising Now, an advocacy group that says it promotes transparency in health care and that is a fierce opponent of ICER’s, is expected to face off with the self-professed “watchdog of drug pricing” as it reviews three drugs for Duchenne muscular dystrophy.

Dozens of Duchenne patients and their families — many of whom also express concern that ICER’s review could undermine insurers’ already tepid interest in the treatments — are also expected to be in attendance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： FDA has safety concerns on CRISPR

focus

WSS

Congress considering partial increase for doctor pay in Medicare

Study gives hint on South Asians’ higher risk of cardiovascular disease

The FDA weighs the risks of candy

CDC recommends rationing of RSV shot due to shortages

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Biden's order seeks to regulate AI risk without stifling innovation

focus

comprehensive

focus

Supreme Court strikes down use of affirmative action

Long Covid research funding gets a major boost from NIH

Continuity nursing helped my family in our darkest PICU moments

Readout Newsletter: XBI biotech index, Akero Therapeutics

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: What happened with Sarepta's Duchenne data

At least 13 dead in Texas as scorching temps continue

Telehealth options flood the market as retailers push virtual care

focus

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Why Eli Lilly’s earnings didn’t quite live up to the hype

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Meta's Zuckerberg and Chan on track to put $50 billion into science

Resistance to opioid

STAT Boddities: What happens to the brain when we get scared?

Wikipedia

leisure time

focus

leisure time